Conversion resection for patients with hepatocellular carcinoma and inferior vena cava tumor thrombus: a consecutive case series  

作　　者：Xiaoyun Zhang Wei Peng Chuan Li Wusheng Lu Zhiping Li Jiayin Yang Tianfu Wen 

机构地区：[1]Department of Liver Surgery and Liver Transplantation Center,West China Hospital of Sichuan University,Chengdu,Sichuan 610041,China [2]Laboratory of Liver Transplantation,Frontiers Science Center for Disease-Related Molecular Network,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China [3]Laboratory of Pathology,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China [4]Department of Radiation Oncology,Cancer Center,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China

出　　处：《Chinese Medical Journal》2022年第12期1486-1488,共3页中华医学杂志（英文版）

基　　金：This study was supported by grants from the National Natural Science Foundation of China(Nos.81900463 and 81800449);the Science and Technological Supports Projectof SichuanProvince(No.2020YFS0133);Post-Doctor Research Project,West China Hospital,Sichuan University(No.2019HXBH004).

摘　　要：To the Editor:The incidence of hepatocellular carcinoma(HCC)with inferior vena cava tumor thrombus(IVCTT)is.approximately 1.4%.Owing to direct cancercll dissemination into the systemic circulation,HCC-IVCTT is frequently associated with synchronous and metachronous extrahepatic metastasis.Without treatment,the median survival time is only 3 months for patients with HCC-IVCTT.

关 键 词：THROMBUS PATIENTS HEPATOCELLULAR 

分 类 号：R735.7[医药卫生—肿瘤]